Correlation of Treatment Dose Enoxaparin with Anti-Xa Concentrations in Adult Hemodialysis Inpatients

IF 0.4 Q4 PHARMACOLOGY & PHARMACY
Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz
{"title":"Correlation of Treatment Dose Enoxaparin with Anti-Xa Concentrations in Adult Hemodialysis Inpatients","authors":"Paul E. Brumley, Miroslav A. Anguelov, Jason P. Hecht, Dane L. Shiltz","doi":"10.13189/APP.2014.020401","DOIUrl":null,"url":null,"abstract":"Enoxaparin, a low-molecular-weight-heparin, is being used in hemodialysis patients despite a lack of guideline or manufacturer dose recommendations. Due to enoxaparin's renal excretion, the possibility of accumulating anti-Xa concentrations in hemodialysis patients using enoxaparin creates a hemorrhagic risk, calling for more research. The objectives of this study are to determine the correlation between treatment dose enoxaparin use and anti-Xa concentrations within the defined therapeutic range in patients receiving chronic, scheduled hemodialysis to determine the degree of change in anti-Xa concentrations in those cases where a concentration was obtained before and after a specific hemodialysis session, and to determine if there is evidence of enoxaparin accumulation over the course of treatment. This was a retrospective cohort study. Patients that were admitted to Indiana University Health facilities in a two-year period were identified from a Cerner query for inclusion eligibility. Inclusion criteria involved patients that received therapeutic dose enoxaparin based on actual body weight on a once daily basis, maintained a scheduled hemodialysis regimen, and had an anti-Xa concentration obtained after at least one enoxaparin dose. Despite lacking statistical significance, the data collected from this study depicts trends which can be utilized to guide future studies. The results of this study suggest that hemodialysis does not effectively remove enoxaparin.","PeriodicalId":7378,"journal":{"name":"Advances in Pharmacology and Pharmacy","volume":"18 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacology and Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13189/APP.2014.020401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Enoxaparin, a low-molecular-weight-heparin, is being used in hemodialysis patients despite a lack of guideline or manufacturer dose recommendations. Due to enoxaparin's renal excretion, the possibility of accumulating anti-Xa concentrations in hemodialysis patients using enoxaparin creates a hemorrhagic risk, calling for more research. The objectives of this study are to determine the correlation between treatment dose enoxaparin use and anti-Xa concentrations within the defined therapeutic range in patients receiving chronic, scheduled hemodialysis to determine the degree of change in anti-Xa concentrations in those cases where a concentration was obtained before and after a specific hemodialysis session, and to determine if there is evidence of enoxaparin accumulation over the course of treatment. This was a retrospective cohort study. Patients that were admitted to Indiana University Health facilities in a two-year period were identified from a Cerner query for inclusion eligibility. Inclusion criteria involved patients that received therapeutic dose enoxaparin based on actual body weight on a once daily basis, maintained a scheduled hemodialysis regimen, and had an anti-Xa concentration obtained after at least one enoxaparin dose. Despite lacking statistical significance, the data collected from this study depicts trends which can be utilized to guide future studies. The results of this study suggest that hemodialysis does not effectively remove enoxaparin.
成人血液透析住院患者依诺肝素治疗剂量与抗xa浓度的相关性
依诺肝素是一种低分子量肝素,尽管缺乏指南或制造商剂量推荐,但仍被用于血液透析患者。由于依诺肝素的肾脏排泄,在使用依诺肝素的血液透析患者中积累抗xa浓度的可能性产生出血风险,需要更多的研究。本研究的目的是确定慢性有计划血液透析患者治疗范围内依诺肝素使用剂量与抗xa浓度之间的相关性,以确定在特定血液透析之前和之后获得浓度的病例中抗xa浓度的变化程度,并确定在治疗过程中是否有依诺肝素积累的证据。这是一项回顾性队列研究。通过Cerner查询确定纳入资格,确定两年内入住印第安纳大学卫生设施的患者。纳入标准包括每日一次根据实际体重接受依诺肝素治疗剂量,维持预定的血液透析方案,并在至少一次依诺肝素剂量后获得抗xa浓度的患者。尽管缺乏统计意义,但本研究收集的数据描绘了可以用来指导未来研究的趋势。本研究结果提示血液透析不能有效去除依诺肝素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Pharmacology and Pharmacy
Advances in Pharmacology and Pharmacy PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
31
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信